Novita Pharmaceuticals, Inc.
Clinical trials sponsored by Novita Pharmaceuticals, Inc., explained in plain language.
-
New combo therapy shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug, NP-G2-044, given alone or with an immunotherapy (anti-PD-1) in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to find the safest dose and check for early signs of tumor shri…
Phase: PHASE1, PHASE2 • Sponsor: Novita Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 11:17 UTC
-
New hope for hard-to-treat ovarian cancer: experimental combo shows promise
Disease control OngoingThis study tests whether adding the experimental drug NP-G2-044 (Prilukae) to standard chemotherapy (PLD) can help people with platinum-resistant ovarian cancer, a type that has stopped responding to initial treatments. About 380 participants will receive either the combination o…
Phase: PHASE2, PHASE3 • Sponsor: Novita Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 18, 2026 12:00 UTC